预测克罗恩病患者维多珠单抗治疗结局的评分系统的开发与验证
研究基于GEMINI 2试验814例活动性克罗恩病患者开发评分系统,并在VICTORY观察队列366例中验证,用于识别接受维多珠单抗治疗26周后应答的患者。验证队列中临床缓解AUC为0.67,无激素缓解AUC为0.66,黏膜愈合AUC为0.72,临床缓解伴黏膜愈合AUC为0.73,无激素临床缓解伴黏膜愈合AUC为0.75。
要点
- 评分系统包含5个因素:未用过TNF拮抗剂、无肠道手术史、无瘘管病史、基线白蛋白水平、基线CRP水平。
- 验证队列中评分≥13分识别临床缓解的敏感性为92%,识别黏膜愈合的敏感性为98%。
- 评分系统用于识别维多珠单抗治疗26周后可能应答的克罗恩病患者。
核心结论
- 研究开发并验证了一个评分系统,用于识别接受26周维多珠单抗治疗后最可能应答的克罗恩病患者。
- 需要进一步研究以优化该评分系统在特定人群中的准确性并确定其成本效益。
研究设计与样本
- 数据来自GEMINI 2 III期试验中接受维多珠单抗治疗26周的活动性克罗恩病患者(n=814),进行逻辑回归分析以识别与临床缓解、无激素缓解和持久缓解相关的因素(推导集)。
- 使用这些数据开发临床决策支持工具,并在一个独立的临床实践观察队列(VICTORY队列)中验证,该队列包含366例接受维多珠单抗治疗26周的活动性克罗恩病患者。
- 使用受试者工作特征曲线下面积(AUC)分析评估该工具识别临床缓解、无激素缓解、黏膜愈合(MH)、临床缓解伴MH或无激素缓解伴MH患者的能力。
- 主要结局是开发并验证一组与活动性克罗恩病患者接受维多珠单抗治疗后实现缓解相关的因素。
主要发现
- 推导分析中识别出与缓解相关的因素:既往未使用肿瘤坏死因子拮抗剂(+3分)、无既往肠道手术(+2分)、无既往瘘管性疾病(+2分)、基线白蛋白水平(每g/L +0.4分)、基线C反应蛋白浓度(3.0至10.0 mg/L之间减0.5分,>10.0 mg/L减3.0分)。
- 验证集中,模型识别临床缓解患者的AUC为0.67,无激素缓解患者的AUC为0.66,黏膜愈合患者的AUC为0.72,临床缓解伴黏膜愈合患者的AUC为0.73,无激素临床缓解伴黏膜愈合患者的AUC为0.75。
- cutoff值13分识别维多珠单抗治疗后临床缓解患者的敏感性为92%,无激素缓解患者的敏感性为94%,黏膜愈合患者的敏感性为98%,临床缓解伴黏膜愈合患者的敏感性为100%,无激素临床缓解伴黏膜愈合患者的敏感性为100%。
关键数值与推荐
- 既往未使用肿瘤坏死因子拮抗剂:+3分。
- 无既往肠道手术:+2分。
- 无既往瘘管性疾病:+2分。
- 基线白蛋白:每g/L +0.4分。
- 基线C反应蛋白:3.0至10.0 mg/L之间减0.5分,>10.0 mg/L减3.0分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以优化该评分系统在特定人群中的准确性并确定其成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely to respond to different therapies. We created and validated a scoring system to identify patients with Crohn's disease (CD) who respond to vedolizumab. METHODS: We collected data from the GEMINI 2 phase 3 trial of patients with active CD treated with vedolizumab for 26 weeks (n = 814) and performed logistic regression analysis to identify factors associated with clinical, steroid-free, and durable remission (derivation set). We used these data to develop a clinical decision support tool, which we validated using data from 366 participants in a separate clinical practice observational cohort of patients with active CD treated with vedolizumab for 26 weeks (the VICTORY cohort). We evaluated the ability of this tool to identify patients in clinical remission or corticosteroid-free remission, or those with mucosal healing (MH), clinical remission with MH, or corticosteroid-free remission with MH after vedolizumab therapy using receiver operating characteristic area under the curve (AUC) analyses. The primary outcome was to develop and validate a list of factors associated with achieving remission by vedolizumab in patients with active CD. RESULTS: In the derivation analysis, we identified absence of previous treatment with a tumor necrosis factor antagonist (+3 points), absence of prior bowel surgery (+2 points), absence of prior fistulizing disease (+2 points), baseline level of albumin (+0.4 points per g/L), and baseline concentration of C-reactive protein (reduction of 0.5 points for values between 3.0 and 10.0 mg/L and 3.0 points for values >10.0 mg/L) as factors associated with remission. In the validation set, our model identified patients in clinical remission with an AUC of 0.67, patients in corticosteroid-free remission with an AUC of 0.66, patients with MH with an AUC of 0.72, patients in clinical remission with MH with an AUC of 0.73, and patients in corticosteroid-free clinical remission with MH with an AUC of 0.75. A cutoff value of 13 points identified patients in clinical remission after vedolizumab therapy with 92% sensitivity, patients in corticosteroid-free remission with 94% sensitivity, patients with MH with 98% sensitivity, patients with clinical remission and MH with 100% sensitivity, and patients with corticosteroid-free clinical remission with MH with 100% sensitivity. CONCLUSIONS: We developed and validated a scoring system to identify patients with CD most likely to respond to 26 weeks of vedolizumab therapy. Further studies are needed to optimize its accuracy in select populations and determine its cost-effectiveness.
引用
- Dulai PS, Boland BS, Singh S, et al. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018. PMID: 29857091. doi:10.1053/j.gastro.2018.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。